Home › All Companies › BAX

BAXTER INTERNATIONAL INC (BAX)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-08

Key Insights

  • Baxter approved a new Executive Severance and Change in Control Plan effective May 4, 2026, which supersedes the prior plan and expands severance protections by including resignations for 'Good Reason' and clarifying that position eliminations constitute qualifying terminations.
  • CEO Andrew Hider's offer letter was amended to increase healthcare coverage payments from 18 to 24 months in non-change-of-control terminations, signaling potential executive retention concerns or competitive market pressures for leadership talent.
  • The new plan maintains tiered severance structures with enhanced CIC protections (2.0x multiplier for most executives, 1.5x for interim CFO Zielinski post-promotion) and includes restrictive covenants but notably excludes excise tax gross-ups, which could reduce total severance liabilities.
  • Interim CFO Anita Zielinski receives preferential treatment with reduced multipliers upon ceasing interim duties, suggesting an anticipated transition in CFO responsibilities that may signal organizational restructuring or permanent appointment timeline.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Current Report Filed: 2026-04-30

Key Insights

  • Baxter reported Q1 2026 earnings on April 30, 2026, with detailed financial results furnished via press release, indicating standard quarterly reporting cadence with no apparent material surprises flagged in the filing.
  • The Board declared a quarterly cash dividend of $0.01 per share payable July 1, 2026, demonstrating continued capital return to shareholders despite the modest per-share amount suggesting either a special circumstance or dividend restructuring.
  • Anita A. Zielinski is signing as Interim Chief Financial Officer, indicating CFO transition at the company that warrants monitoring for potential leadership or strategic changes, though no explanation of the interim status is provided in this filing.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Quarterly Report Filed: 2026-04-30

Key Insights

  • The filing is dated April 30, 2026 for Q1 2026 (ended March 31, 2026), containing standard XBRL formatted financial data across three business segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals.
  • The document references multiple material items including derivative instruments, hedging activities, discontinued operations, property and equipment valuations, and various intangible assets including customer relationships, patents, and trade names.
  • The filing shows continued activities related to kidney care transition services and manufacturing agreements (referenced with January 31, 2025 dates), along with environmental cleanup obligations at Superfund sites and ethylene oxide exposure matters requiring ongoing disclosure.
  • Baxter maintains a revolving credit facility and commercial paper program as of March 31, 2026, with accumulated other comprehensive income adjustments including translation adjustments, defined benefit plan adjustments, and cash flow hedge impacts tracked across multiple reporting periods.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Current Report Filed: 2026-03-19

Key Insights

  • Baxter International Inc. filed an 8-K disclosure regarding a stockholder engagement presentation to be provided to certain shareholders on or after March 19, 2026.
  • The company did not provide any specific financial or operational updates in this 8-K filing, suggesting it may be a routine shareholder communication.
  • There were no indications of any material agreements, leadership changes, or earnings surprises that would be considered significant news for investors.
Sentiment: Neutral Significance: 2/10
View Original Filing →
Current Report Filed: 2026-03-16

Key Insights

  • Baxter International announced the departure of its CFO, Joel Grade, who will transition into an advisory role through April 2026. This transition does not appear to be due to any disagreement with the company's management or board.
  • The company has appointed Anita Zielinski, the current Senior Vice President and Chief Accounting Officer, as the interim CFO while it conducts a search for a permanent replacement. This interim arrangement provides continuity during the leadership change.
  • Baxter has agreed to provide severance benefits to the departing CFO in line with the company's Executive Severance Plan, subject to certain conditions. This suggests the transition was handled in an orderly manner.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • The filing indicates that Joel T. Grade, the Executive Vice President and Chief Financial Officer of Baxter International Inc. (BAX), disposed of 8,153 shares of the company's common stock on March 6, 2026 to cover tax withholding obligations related to the vesting of restricted stock units.
  • Following the reported transaction, Grade continues to beneficially own 271,674 shares of Baxter International, suggesting he maintains a significant equity stake in the company.
  • The timing and nature of this insider sale transaction may be worth monitoring, as insider selling can sometimes signal management's sentiment about the company's future prospects.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • The reporting person, Reazur Rasul, who holds the position of EVP and Group President of Healthcare at Baxter International Inc. (BAX), has disposed of 12,674 shares of common stock to cover tax withholding obligations on vested restricted stock units.
  • The disposition of shares represents a relatively small portion (approximately 9%) of the reporting person's total beneficial ownership of 125,557 shares, suggesting no significant change in their overall position in the company.
  • The timing of the transaction, which occurred on March 6, 2026, is consistent with the settlement of previously granted equity awards, indicating a routine event related to executive compensation.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • The reporting person, David S. Rosenbloom, is an Executive Vice President and General Counsel of Baxter International Inc., indicating his importance and influence within the company.
  • Rosenbloom disposed of 6,620 shares of Baxter's common stock on March 6, 2026, likely to cover tax withholding obligations from the vesting of restricted stock units granted in 2024 and 2025.
  • Following the reported transaction, Rosenbloom still holds a substantial 138,216 shares of Baxter's common stock, suggesting his continued commitment and alignment with the company's long-term interests.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • The reporting person, Maria Cecilia Soriano, is an officer of Baxter International Inc. (BAX), holding the title of Group President, ITT & Pharma.
  • Soriano disposed of 2,848 shares of Baxter's common stock on March 6, 2026 to cover the withholding of taxes from the vesting of restricted stock units granted in 2024 and 2025.
  • Following the reported transaction, Soriano continues to beneficially own 75,045 shares of Baxter's common stock directly.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-03-10

Key Insights

  • The reporting person, Anita A. Zielinski, who is the SVP, CAO and Controller of Baxter International Inc., has reported a transaction where she forfeited 1,932 shares of common stock to cover withholding taxes, indicating an equity-based compensation event.
  • The reported transaction occurred on March 6, 2026, suggesting the vesting of restricted stock units granted to the reporting person on March 6, 2025.
  • The reporting person continues to hold 46,281 shares of Baxter International Inc. common stock following the reported transaction, indicating she maintains a significant equity stake in the company.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-18

Key Insights

  • The reporting person, Michael R. McDonnell, who is a director of Baxter International Inc. (BAX), received a grant of 1,811 fully vested shares of the company's common stock.
  • This transaction indicates that a director is taking a long-term position in the company's stock, which could be seen as a positive signal for investors.
  • The timing of the transaction, occurring on February 13, 2026, suggests the director may have confidence in the company's future performance.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-02-12

Key Insights

  • Baxter International Inc. announced the appointment of Michael R. McDonnell to its Board of Directors, effective February 13, 2026. McDonnell has a strong background as a CFO of several major healthcare companies.
  • The company also announced the resignation of Cathy R. Smith and Stephen H. Rusckowski from the Board, effective February 13, 2026. The reasons for their departures were not due to any disagreements with the company.
  • Baxter declared a quarterly cash dividend of $0.01 per share of common stock, payable on April 1, 2026, to stockholders of record as of February 27, 2026.
Sentiment: Positive Significance: 6/10
View Original Filing →
Annual Report Filed: 2026-02-12

Key Insights

  • Baxter International Inc. (BAX) reported a 33.33% increase in operating income for the fiscal year 2025, indicating improved profitability.
  • The company's long-term debt and lease obligations, excluding current maturities, increased by a significant amount in 2025, potentially raising concerns about its financial leverage.
  • Baxter announced the divestiture of its Kidney Care and BioPharmaSolutions business segments, signaling a strategic shift in the company's focus.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.